Literature DB >> 27865780

RasIns: Genetically Encoded Intrabodies of Activated Ras Proteins.

Mehmet Cetin1, William E Evenson2, Garrett G Gross1, Farzad Jalali-Yazdi3, Daniel Krieger2, Don Arnold1, Terry T Takahashi2, Richard W Roberts4.   

Abstract

K- and H-Ras are the most commonly mutated genes in human tumors and are critical for conferring and maintaining the oncogenic phenotype in tumors with poor prognoses. Here, we design genetically encoded antibody-like ligands (intrabodies) that recognize active, GTP-bound K- and H-Ras. These ligands, which use the 10th domain of human fibronectin as their scaffold, are stable inside the cells and when fused with a fluorescent protein label, the constitutively active G12V mutant H-Ras. Primary selection of ligands against Ras with mRNA display resulted in an intrabody (termed RasIn1) that binds with a KD of 2.1μM to H-Ras(G12V) (GTP), excellent state selectivity, and remarkable specificity for K- and H-Ras. RasIn1 recognizes residues in the Switch I region of Ras, similar to Raf-RBD, and competes with Raf-RBD for binding. An affinity maturation selection based on RasIn1 resulted in RasIn2, which binds with a KD of 120nM and also retains excellent state selectivity. Both of these intrabodies colocalize with H-Ras, K-Ras, and G12V mutants inside the cells, providing new potential tools to monitor and modulate Ras-mediated signaling. Finally, RasIn1 and Rasin2 both display selectivity for the G12V mutants as compared with wild-type Ras providing a potential route for mutant selective recognition of Ras.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  E10FnIII; Ras; fibronectin; intrabody; mRNA display

Mesh:

Substances:

Year:  2016        PMID: 27865780      PMCID: PMC5798998          DOI: 10.1016/j.jmb.2016.11.008

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  34 in total

Review 1.  KRAS as a Therapeutic Target.

Authors:  Frank McCormick
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

2.  Turning G proteins on and off using peptide ligands.

Authors:  William W Ja; Ofer Wiser; Ryan J Austin; Lily Y Jan; Richard W Roberts
Journal:  ACS Chem Biol       Date:  2006-10-24       Impact factor: 5.100

3.  The fibronectin type III domain as a scaffold for novel binding proteins.

Authors:  A Koide; C W Bailey; X Huang; S Koide
Journal:  J Mol Biol       Date:  1998-12-11       Impact factor: 5.469

Review 4.  G protein mechanisms: insights from structural analysis.

Authors:  S R Sprang
Journal:  Annu Rev Biochem       Date:  1997       Impact factor: 23.643

Review 5.  RAS oncogenes: weaving a tumorigenic web.

Authors:  Yuliya Pylayeva-Gupta; Elda Grabocka; Dafna Bar-Sagi
Journal:  Nat Rev Cancer       Date:  2011-10-13       Impact factor: 60.716

6.  Inhibition of Ras signaling by blocking Ras-effector interactions with cyclic peptides.

Authors:  Punit Upadhyaya; Ziqing Qian; Nicholas G Selner; Sarah R Clippinger; Zhengrong Wu; Roger Briesewitz; Dehua Pei
Journal:  Angew Chem Int Ed Engl       Date:  2015-05-07       Impact factor: 15.336

7.  Antibody-mimetic ligand selected by mRNA display targets DC-SIGN for dendritic cell-directed antigen delivery.

Authors:  Liang Xiao; Kuo-Chan Hung; Terry T Takahashi; Kye-Il Joo; Matthew Lim; Richard W Roberts; Pin Wang
Journal:  ACS Chem Biol       Date:  2013-03-08       Impact factor: 5.100

Review 8.  Dragging ras back in the ring.

Authors:  Andrew G Stephen; Dominic Esposito; Rachel K Bagni; Frank McCormick
Journal:  Cancer Cell       Date:  2014-03-17       Impact factor: 31.743

Review 9.  Adnectins: engineered target-binding protein therapeutics.

Authors:  D Lipovsek
Journal:  Protein Eng Des Sel       Date:  2010-11-10       Impact factor: 1.650

10.  Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS.

Authors:  Tomoyuki Tanaka; Roger L Williams; Terence H Rabbitts
Journal:  EMBO J       Date:  2007-06-14       Impact factor: 11.598

View more
  13 in total

1.  mRNA Display Discovery of a Novel Programmed Death Ligand 1 (PD-L1) Binding Peptide (a Peptide Ligand for PD-L1).

Authors:  Golnaz Kamalinia; Brian J Engel; Anupallavi Srinivasamani; Brian J Grindel; Justin N Ong; Michael A Curran; Terry T Takahashi; Steven W Millward; Richard W Roberts
Journal:  ACS Chem Biol       Date:  2020-04-30       Impact factor: 5.100

Review 2.  Targeting Ras with Macromolecules.

Authors:  Dehua Pei; Kuangyu Chen; Hui Liao
Journal:  Cold Spring Harb Perspect Med       Date:  2018-03-01       Impact factor: 6.915

Review 3.  Illuminating the kinome: Visualizing real-time kinase activity in biological systems using genetically encoded fluorescent protein-based biosensors.

Authors:  Danielle L Schmitt; Sohum Mehta; Jin Zhang
Journal:  Curr Opin Chem Biol       Date:  2020-01-03       Impact factor: 8.822

4.  Chemical acylation of an acquired serine suppresses oncogenic signaling of K-Ras(G12S).

Authors:  Ziyang Zhang; Keelan Z Guiley; Kevan M Shokat
Journal:  Nat Chem Biol       Date:  2022-07-21       Impact factor: 16.174

5.  Discovery of a Bicyclic Peptidyl Pan-Ras Inhibitor.

Authors:  Marina Buyanova; Shurui Cai; Jahan Cooper; Curran Rhodes; Heba Salim; Ashweta Sahni; Punit Upadhyaya; Rui Yang; Amar Sarkar; Na Li; Qi-En Wang; Dehua Pei
Journal:  J Med Chem       Date:  2021-08-20       Impact factor: 8.039

Review 6.  Directing evolution of novel ligands by mRNA display.

Authors:  Golnaz Kamalinia; Brian J Grindel; Terry T Takahashi; Steven W Millward; Richard W Roberts
Journal:  Chem Soc Rev       Date:  2021-06-24       Impact factor: 60.615

Review 7.  Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology.

Authors:  Congcong Zhang; Rina M Ötjengerdes; Julian Roewe; Rebeca Mejias; Andrea L J Marschall
Journal:  BioDrugs       Date:  2020-08       Impact factor: 5.807

Review 8.  Targeted Intracellular Delivery of Antibodies: The State of the Art.

Authors:  Tatiana A Slastnikova; A V Ulasov; A A Rosenkranz; A S Sobolev
Journal:  Front Pharmacol       Date:  2018-10-24       Impact factor: 5.810

Review 9.  Recent advances in the biology and therapy of medullary thyroid carcinoma.

Authors:  Barry Nelkin
Journal:  F1000Res       Date:  2017-12-28

Review 10.  Development and Differentiation in Monobodies Based on the Fibronectin Type 3 Domain.

Authors:  Peter G Chandler; Ashley M Buckle
Journal:  Cells       Date:  2020-03-04       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.